Member Info for Chris0123

Dhub, I have always followed your posts with interest so kind of found it relatively easy to see when there was a slight change in your sentiment for Hemo. I am sure it wasn't wholly obvious to the casual observer but to a regular reader it was very clear. However, on the 9th you felt that discussion with large Pharma had been taking place but it did not break in time and postulated that you felt something might happen in a couple of weeks. By this Friday that couple of weeks will come to an end. Given that you have reduced your holding combined with your prediction and regular mention of FOMO Friday, I wonder that if news breaks you may be in danger of missing out yourself with a diminished holding. Is FOMO something you have considered yourself. It would be a terrible tragedy given the years you have held firm. I do appreciate everyone has their own reason to sell. GL

Https://www.labiotech.eu/in-depth/us-biotech-investment/

This is an interesting article but if reading suggest read all of it. We know the challenges and acknowledge the history and it all clearly resonates with the path Hemogenyx has trodden. However, VS has got through those difficulties with well developed science and fantastic potential. He mentioned being lean and this is referenced. He has raised funds in an early stage biotech environment cited as difficult and has a humdinger of a biotechnology platform in CBR. It won't need much for this coiled spring to leap into action. There's a breeze and tumbleweed at the moment but I think next news will likely be great news, a real catalyst. Sit tight I say, let this time to the heavy lifting. GLA

Dr Sandler said in the II interview that he was going to make a "significant amount of money"💰 for me as an investor as well asv"save lives" told me mortgage people and everything!..don't they say when investing let time do the heavy lifting. It's simply a matter of time now and given time now clinical he will deliver. The science is progressing very well. GLA

Yep JHFH and we still have a seat at the big game might be a cheap seat currently but confident of an upgrade soon. Have a good day.

Https://www.forbes.com/sites/forbesbusinesscouncil/2024/03/15/strategizing-biotech-partnerships-to-help-bring-therapies-to-patients/

When you read this article we should be comforted that VS has got the Clinical Trials partnership right and manufacturing infrastructure right It's the finance partnership that needs some work but early success in CT's might secure what HEMO need on favourable terms. Goodnight all & hang in there, HEMO can do this.

Https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-expands-use-bristol-myers-cancer-therapy-2024-03-15/

Https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-votes-favor-expanded-use-bristol-myers-car-t-therapy-2024-03-15/

An advisory panel met with the FDA today and in a vote 8 to 3 voted in favour of Bristol Myers Sqibb expanding their use of a CAR T therapy for a myeloma condition they are treating. There has been reports about concerns with CAR T but this is a further endorsement of the CRT T based therapies. This is not a ramp for BMS but shoes that yhe FDA recognise that this is a developing therapy which even if not perfect they see fit to allow expansion of its use. This bodes well for Hemo in it's clinical trials. HEMO CAR T is well researched, has approval and can deliver the efficacy required knowing that even big pharma sre not perfect. I will drop another couple of articles for anyone who might be interested. GLA

Are we not using patient's own cells as opposed to donor cells mentioned within the description. GLA

Feels like being in the jaws of an XL Bully dog right now. I hope someone can spare us from being ripped apart very soon. GLA

Always good to hear about the science and it's potential. A great reminder of what could be Haywain.

I was dreading talking to my wife about the run down barn in France which we could buy as a doer upper. Particularly having already managed expectations by dissuading her that the Chateau we had our eyes on was perhaps too much and a Gites might be better. If its looking like a sleeping back under Pont Neuf because I cannot get enough out of Hemo for even a ramshackle barn, then I am toast, or rather croissant in this case. Bon chance everyone, I think we will do okay.

To the shareholders and the onlookers things seem to be in a little bit of disarray. This is fueled heavily by more recent events. Time for the company to grab back control, reset their vision and goals and layout for people (those with money in the company already or any potential prospects) what the strategy is going to be.

Yes, there are a lot of what if's and we know that, but a sense that they know where they are going and how to get there is imperative to avoid any perception of drift which many will take advantage of.

A clear and concise communication is needed right now. GLA

It's history now I guess but the VS tweet some weeks back. just wondering whether this was perhaps in reference to internal wrangling over funding. Maybe alternative funding was available but VS wanted to maintain control a little longer through Phase 1. Therefore, an argument internally the "he won!" I hope we can recover somewhat next week.

Moving forward, any thoughts saying on CBR Patent Approval timescales? GLA

What more can be said about today? The only silver lining is that today is the 29th February, so there will only be a 4 yearly reminder of what took place...this time.....year! Think we should lobby to change it from "leap year" to "plunge year". We'll get there, eventually I am sure but perhaps not with some of the people we should be arriving with. who had simply had enough. GLA

HT - Norman Bates

Is it a possibility that some institutions holding small amounts (to them 10+ million shares say) could be selling enough to put downward pressure on the price and lowering the cost of entry when funding news breaks. So they do not yet commit the big money in advance of JV or funding news but in the meantime cushion future investment cost on say much larger investments. Effectively, they have held the price down by chipping in what is to them small offloads. It would fit as even the most cynical about funding must be bewildered by the static share price and the obvious disconnect between going clinical and the current sp. You don't get major offloading of shares on great news without a reason. Funding requirements have always been there. The funding issues now with clinical go ahead are far less a concern and institutions will know this, they are just not showing their hand other than dropping in sales to keep their much bigger buys (on news) as cheap as possible. GLA

HH - I agree, let's hope we get to the stage of setting a date. Although to be fair what other forum do we have if noone else is really talking to the private investors. Once we start to get a regular flow of updates through clinical trials from the company, there will be less need to speculate on boards like these. GLA

Sorry that was Peter Redmond

Well documented Haywain,. Sir Marc stated at the Interactive Investor interview that they were ready to move forward at "a pace". GLA

Stu I think it's time to raise anchor and set sail for Dogger Bank, picking up IslandGirl along the way. Unless, this is a Norman Bates scenario. If the genuine investors are wrong about the direction of travel for this company, we suck it up and move on. I have said previously, we do not want our noses rubbed in negativity motivated by a hidden agenda (have you declared you are a shorter?) and you are clearly not Martin Lewis on the campaign trail trying to save us from ourselves. You have a motive. If JHFH is right, and many of us believe he is, investors and patients benefit. If you are right, pretty much everyone loses out including the unwell. So, IslandGirl, in a way we are providing funding for cancer research already, direct to the researchers, shorters on the other hand are denying funding and Hemo's chances of earlier success which from your tone is why you should be on Stu's boat. Perhaps move on to an industry that isn't life sciences.

GLA

Life's "too short" Stu but then again so are you.

I can keep these coming.

However, as I have said, this is biotech, high risk, high reward but unfortunately your investment strategy tends to glory in the no news period. Join us on that long crest of the Hemo wave, you might just like it. GLA